132 related articles for article (PubMed ID: 35548965)
1. RAPID LOW-COST DETECTION OF TYPE 2CALR MUTATION BY ALLELE-SPECIFIC RT-PCR FOR DIAGNOSIS OF MYELOPROLIFERATIVE NEOPLASMS.
Dybkov MV; Zavelevich MP; Gluzman DF; Telegeev GD
Exp Oncol; 2022 May; 44(1):83-86. PubMed ID: 35548965
[TBL] [Abstract][Full Text] [Related]
2. [Allele-specific polymerase chain reaction and electrophoretic detection in the detection algorithm clinically significant somatic mutations in the gene of calreticulin (calr).].
Gorbenko AS; Stolyar MA; Olkhovskiy IA; Abdullaev AO; Sudarikov AB; Dunaeva EA; Mironov KO; Shipulin GA
Klin Lab Diagn; 2018; 63(9):588-592. PubMed ID: 30735328
[TBL] [Abstract][Full Text] [Related]
3. Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms.
Trung NT; Quyen DT; Hoan NX; Giang DP; Trang TTH; Velavan TP; Bang MH; Song LH
BMC Med Genet; 2019 Jun; 20(1):115. PubMed ID: 31248375
[TBL] [Abstract][Full Text] [Related]
4. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
5. Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India.
Rabade N; Subramanian PG; Kodgule R; Raval G; Joshi S; Chaudhary S; Mascarenhas R; Tembhare P; Gujral S; Patkar N
Indian J Pathol Microbiol; 2018; 61(2):209-213. PubMed ID: 29676359
[TBL] [Abstract][Full Text] [Related]
6. Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms.
Gángó A; Mózes R; Boha Z; Kajtár B; Timár B; Király PA; Kiss R; Fésüs V; Nagy N; Demeter J; Körösmezey G; Borbényi Z; Marton I; Szőke A; Masszi T; Farkas P; Várkonyi J; Plander M; Pósfai É; Egyed M; Pál K; Radványi G; Hamed A; Csomor J; Matolcsy A; Alpár D; Bödör C
Leuk Res; 2018 Feb; 65():42-48. PubMed ID: 29306106
[TBL] [Abstract][Full Text] [Related]
7. Conformation sensitive gel electrophoresis for the detection of calreticulin mutations in BCR-ABL1-negative myeloproliferative neoplasms.
Zakaria NA; Rosle NA; Siti Asmaa MJ; Aziee S; Haiyuni MY; Samat NA; Husin A; Hassan R; Ramli M; Mohamed Yusoff S; Ibrahim IK; Al-Jamal HAN; Johan MF
Int J Lab Hematol; 2021 Dec; 43(6):1451-1457. PubMed ID: 34125992
[TBL] [Abstract][Full Text] [Related]
8. Rapid and sensitive detection of calreticulin type 1 and 2 mutations by real-time quantitative PCR.
Zinke M; Nageswaran V; Reinhardt R; Burmeister T
Mol Diagn Ther; 2015 Oct; 19(5):329-34. PubMed ID: 26294037
[TBL] [Abstract][Full Text] [Related]
9. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
10. Frequencies, Laboratory Features, and Granulocyte Activation in Chinese Patients with CALR-Mutated Myeloproliferative Neoplasms.
Guo H; Chen X; Tian R; Chang J; Li J; Tan Y; Xu Z; Ren F; Zhao J; Pan J; Zhang N; Wang X; He J; Yang W; Wang H
PLoS One; 2015; 10(9):e0138250. PubMed ID: 26375990
[TBL] [Abstract][Full Text] [Related]
11. Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms.
Frawley T; O'Brien CP; Conneally E; Vandenberghe E; Percy M; Langabeer SE; Haslam K
Genet Test Mol Biomarkers; 2018 Feb; 22(2):98-103. PubMed ID: 29323541
[TBL] [Abstract][Full Text] [Related]
12. Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features.
Loghavi S; Bueso-Ramos CE; Kanagal-Shamanna R; Ok CY; Salim AA; Routbort MJ; Mehrotra M; Verstovsek S; Medeiros LJ; Luthra R; Patel KP
Am J Clin Pathol; 2016 Mar; 145(3):418-27. PubMed ID: 27124925
[TBL] [Abstract][Full Text] [Related]
13. A rapid, highly accurate method for quantifying CALR mutant allele burden in persons with myeloproliferative neoplasms.
Yao QM; Zhou J; Gale RP; Li JL; Li LD; Li N; Chen SS; Ruan GR
Hematology; 2015 Oct; 20(9):517-22. PubMed ID: 25860380
[TBL] [Abstract][Full Text] [Related]
14. Screening PCR Versus Sanger Sequencing: Detection of CALR Mutations in Patients With Thrombocytosis.
Jeong JH; Lee HT; Seo JY; Seo YH; Kim KH; Kim MJ; Lee JH; Park J; Hong JS; Park PW; Ahn JY
Ann Lab Med; 2016 Jul; 36(4):291-9. PubMed ID: 27139600
[TBL] [Abstract][Full Text] [Related]
15. Low
Makarik TV; Abdullaev AO; Nikulina EE; Treglazova SA; Stepanova EE; Subortseva IN; Kovrigina AM; Melikyan AL; Kulikov SM; Sudarikov AB
Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33921387
[No Abstract] [Full Text] [Related]
16. Rapid and sensitive detection of CALR exon 9 mutations using high-resolution melting analysis.
Lim KH; Lin HC; Chen CG; Wang WT; Chang YC; Chiang YH; Lin CS; Su NW; Su YW; Lin J; Chang YF; Chang MC; Hsieh RK; Kuo YY; Chou WC
Clin Chim Acta; 2015 Feb; 440():133-9. PubMed ID: 25447704
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.
Agarwal R; Blombery P; McBean M; Jones K; Fellowes A; Doig K; Forsyth C; Westerman DA
Ann Hematol; 2017 May; 96(5):725-732. PubMed ID: 28161773
[TBL] [Abstract][Full Text] [Related]
18. Calreticulin exon 9 mutations in myeloproliferative neoplasms.
Ha JS; Kim YK
Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276
[TBL] [Abstract][Full Text] [Related]
19. Clinical validation of a multipurpose assay for detection and genotyping of CALR mutations in myeloproliferative neoplasms.
Mehrotra M; Luthra R; Singh RR; Barkoh BA; Galbincea J; Mehta P; Goswami RS; Jabbar KJ; Loghavi S; Medeiros LJ; Verstovsek S; Patel KP
Am J Clin Pathol; 2015 Nov; 144(5):746-55. PubMed ID: 26486739
[TBL] [Abstract][Full Text] [Related]
20. CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms.
Belcic Mikic T; Pajic T; Sever M
Sci Rep; 2019 Dec; 9(1):19838. PubMed ID: 31882869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]